摘要
Abstract
Objective:To assess the effectiveness and safety of Delisheng Injection combined with chemother-apy in the treatment of NSCLC. Methods:Databases from PubMed,EMBase,and CBM, VIP,Wanfang,and CNKI were searched.Two authors independently collected and crosschecked the randomly controlled trials that met the enrolling criteria. The methodological quality of these trials was evaluated and Meta-analysis was performed by using the Cochrane Collaboration’s RevMan 5.0. Results:767 participants (patients) in 10 homogeneous studies were included.The meta-analysis of the 10 studies showed that, when Delisheng Injection combined with chemotherapy group was compared with chemotherapy group,the relative risk (RR)to the effective rate (CR+PR) was 1.29 and 95% confidence interval(CI) was [1.11,1.50]; RR to KPS scale improved rate was 1.81 and 95%CI was [1.53,2.15]. The incidence of adverse reactions was lower in patients treated with Delisheng Injection com-bined with chemotherapy than in those treated with chemotherapy alone. Significant difference was noted in the incidence of alopecia,liver damage phlebitis,between the two groups of patients. Conclusion: Delisheng Injec-tion combined with chemotherapy has beneficial effects in the treatment of NSCLC. However,due to the limited quantity and quality of the included studies, large-scale multi-center randomized trials are still needed to verify it.关键词
得力生注射液/非小细胞肺癌/化疗/meta分析Key words
Delisheng Injection/Non-small cell lung cancer/Chemotherapy/Meta-analysis分类
医药卫生
